Valuation: Clene Inc.

Market Cap 8.01Cr 7.01Cr 6.46Cr 5.97Cr 11Cr 764.14Cr 12Cr 77Cr 30Cr 376.44Cr 30Cr 29Cr 1.29TCr P/E 2026 *
-3.51x
P/E 2027 * -4.26x
Enterprise Value 6.67Cr 5.84Cr 5.38Cr 4.97Cr 9.43Cr 636.34Cr 9.59Cr 64Cr 25Cr 313.48Cr 25Cr 25Cr 1.08TCr EV / Sales 2026 *
322x
EV / Sales 2027 * 2.48x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week+2.79%
Current month+1.87%
1 month+14.00%
3 months+2.62%
6 months-1.95%
Current year+6.81%
1 week 5.83
Extreme 5.83
6.38
1 month 5.41
Extreme 5.41
6.46
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
17
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Director/Board Member 78 01/03/2013
Chairman 65 19/05/2021
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Founder

45,000 0.3522%
11/06Free

Chief Financial Officer

15,000 0.1174%
11/06Free

Chief Executive Officer

65,000 0.5087%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+2.79%+66.76%-61.06% 8.01Cr
-4.14%-8.06%+57.35%+117.24% 5.46TCr
+1.84%-0.66%+75.79%+93.87% 5.49TCr
-2.24%+3.59%+19.60%+466.72% 2.51TCr
-1.60%-6.21%-19.69%-14.84% 2.31TCr
+2.43%+1.06%+47.70%-0.11% 1.99TCr
-3.19%0.00%+33.99%-26.87% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
-1.05%+1.16%+25.08%+196.28% 1.42TCr
+8.74%+3.51%+53.81% - 1.54TCr
Average -0.57%+0.03%+55.55%+125.38% 2.41TCr
Weighted average by Cap. -0.91%-1.46%+55.05%+137.71%

Financials

2026 *2027 *
Net sales 2L 2L 2L 2L 3L 1.98Cr 3L 19.99L 8L 97.45L 8L 8L 3.35Cr 2.36Cr 2.07Cr 1.91Cr 1.76Cr 3.34Cr 225.5Cr 3.4Cr 23Cr 8.95Cr 111.09Cr 8.88Cr 8.68Cr 381.91Cr
Net income -2.51Cr -2.19Cr -2.02Cr -1.87Cr -3.55Cr -239.33Cr -3.61Cr -24Cr -9.5Cr -117.9Cr -9.42Cr -9.22Cr -405.32Cr -2.75Cr -2.41Cr -2.22Cr -2.05Cr -3.9Cr -262.73Cr -3.96Cr -27Cr -10Cr -129.43Cr -10Cr -10Cr -444.96Cr
Net Debt -1.34Cr -1.17Cr -1.08Cr -99.85L -1.89Cr -127.8Cr -1.93Cr -13Cr -5.07Cr -63Cr -5.03Cr -4.92Cr -216.44Cr -2.14Cr -1.87Cr -1.73Cr -1.59Cr -3.03Cr -204.1Cr -3.08Cr -21Cr -8.1Cr -100.55Cr -8.04Cr -7.86Cr -345.66Cr
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
10/26/10 $6.270 +0.32% 33,705
09/26/09 $6.250 +2.80% 50,244
08/26/08 $6.080 -0.65% 41,043
07/26/07 $6.120 +1.83% 71,775
06/26/06 $6.010 -1.48% 40,801
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.270USD
Average target price
32.20USD
Spread / Average Target
+413.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock